Clinical Trial

Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-24; most recent amendment 2026-02-12.
Trial Details
NCT Number NCT07047508
Lead Sponsor Boehringer Ingelheim
Conditions Heart Failure, Preserved Ejection Fraction
Enrollment 3,000 participants
Start Date 2028-01-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13